Compare BioNano Genomics Inc (BNGO) vs Palo Alto Networks Inc (PANW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Palo Alto Networks Inc — how do they compare? BioNano Genomics Inc trades at $1.18 (market cap $13.66M), while Palo Alto Networks Inc trades at $388.01 (market cap $312.80B). The key difference: Palo Alto Networks Inc is far larger — about 22899× BioNano Genomics Inc's market cap, and Palo Alto Networks Inc is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | PANW | |
|---|---|---|
Market Cap | $13.66M | $312.80B |
Sector | Health | Technology |
52-Week High | $4.92 | $385.04 |
52-Week Low | $1.06 | $141.67 |
Enterprise Value | $16.26M | $311.76B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.195, up 3.02% today, with a bullish technical signal from moving averages but a neutral oscillator stance. The company shows improving financial trends, with net losses narrowing to -$26.40M in 2025 from -$232M in 2023, and recent earnings beats. Revenue stabilized around $29M, while cash flow trends indicate reduced operational cash burn. Analyst sentiment is positive, with 57% buy ratings.
The outlook for BNGO hinges on sustaining revenue growth and achieving profitability, supported by strategic hires and debt retirement. Key risks include persistent negative margins and high cash burn. With a low P/S of 0.31, the stock offers value if execution improves, but investors face volatility from operational challenges and competitive pressures.
Palo Alto Networks (PANW) trades at $386.64, up 0.42% today, nearing its 52-week high with strong bullish technical signals. Recent earnings beats, including Q1 2026 EPS of $0.85 versus $0.793 expected, and robust revenue growth to $9.22B in 2025 highlight fundamental strength. Positive sentiment is driven by AI cybersecurity demand, as noted in recent news, though valuation ratios like P/E of 333.74 remain elevated.
Outlook is optimistic due to cybersecurity tailwinds and AI innovation, but risks include high valuation, integration costs from acquisitions, and regulatory scrutiny, such as China's cybersecurity review. Analyst consensus is strongly bullish with a $344.94 price target, suggesting potential downside from current levels amid growth execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Palo Alto Networks Inc
Palo Alto Networks is a pure-play cybersecurity vendor that sells security appliances, subscriptions, and support into enterprises, government entities, and service providers. The company's product portfolio includes firewall appliances, virtual firewalls, endpoint protection, cloud security, and cybersecurity analytics. The Santa Clara, California, firm was established in 2005 and sells its products worldwide.
Read more on PANW →
